Pacira Pharmaceuticals (PCRX) Posts Narrower than Expected Q3 Loss; Guides FY11 Revs
Pacira Pharmaceuticals (NASDAQ: PCRX) reported Q3 EPS of ($0.55), $0.04 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $3.96 million versus the consensus estimate of $3.97 million.
Sees FY2011 revenue of $14-$16 million, versus the consensus of $15.50 million.
Sees FY2011 revenue of $14-$16 million, versus the consensus of $15.50 million.